Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb;75(2):305-312.
doi: 10.1007/s13304-022-01379-2. Epub 2022 Oct 22.

ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma

Vittoria Matilde Piva #  1   2 , Maria Caterina De Grandis #  1   2 , Irene Sole Zuin  1   3 , Valentina Angerilli  4 , Floriana Nappo  2 , Rita Alfieri  5 , Selma Ahcene Djaballah  6 , Sabina Murgioni  2 , Francesca Bergamo  2 , Matteo Fassan  4   7 , Michele Valmasoni #  1   3 , Sara Lonardi #  8
Affiliations
Review

ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma

Vittoria Matilde Piva et al. Updates Surg. 2023 Feb.

Abstract

Gastroesophageal adenocarcinoma is a challenging disease due to its poor prognosis and the presence of few therapeutic options. For these reasons, it is mandatory to identify the subgroup of patients who are at high risk for relapse after curative-intention surgery. In the last years, liquid biopsy has aroused great interest in cancer treatment for its feasibility and the possibility to capture tumor heterogeneity in a real-time way. In postoperative setting, the interest is directed to the identification of Minimal Residual Disease (MRD), defined as isolated or small cluster of cancer cells that residues after curative-intention surgery, and are undetectable by conventional radiological and clinical exams. This review wants to summarize current evidence on the use of liquid biopsy in gastroesophageal cancer, focusing on the detection of ctDNA in the postoperative setting and its potential role as a guide for treatment decision.

Keywords: Esophageal cancer; Gastric cancer; Liquid biopsy; Minimal residual disease; ctDNA.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI
    1. Siewert JR, Hölscher AH, Becker K, Gössner W (1987) [Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg 58(1):25–32
    1. Smyth EC, Gambardella V, Cervantes A, Fleitas T (2021) Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol 32(5):590–599. https://doi.org/10.1016/j.annonc.2021.02.004 - DOI
    1. Smyth EC, Verheij M, Allum W et al (2016) Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(August):v38–v49. https://doi.org/10.1093/annonc/mdw350 - DOI
    1. Shapiro J, van Lanschot JJB, Hulshof MCCM et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098. https://doi.org/10.1016/S1470-2045(15)00040-6 - DOI

MeSH terms

LinkOut - more resources